JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Inicio・Lista de Acciones・CorMedix Inc

CorMedix Inc

Cerrado

SectorSanidad

8.18 5.28

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

7.77

Máximo

8.52

Métricas clave
By Trading Economics
Ingresos	89M 109M
Ventas	65M 104M
P/B Media del Sector	3.511 90.422
Margen de beneficios	104.112
Empleados	64
EBITDA	37M 57M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+83.63% upside

Dividendos
By Dow Jones
Próximas Ganancias	24 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-257M 611M
Apertura anterior	2.9
Cierre anterior	8.18

Noticias sobre sentimiento de mercado

By Acuity

56%

44%

295 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

9.2 / N/A Soporte y Resistencia

CorMedix Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 feb 2026, 23:52 UTC

Adquisiciones, fusiones, absorciones

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 feb 2026, 23:52 UTC

Adquisiciones, fusiones, absorciones

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 feb 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 feb 2026, 23:38 UTC

Charlas de Mercado

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 feb 2026, 23:28 UTC

Charlas de Mercado

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 feb 2026, 23:23 UTC

Ganancias

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 feb 2026, 22:57 UTC

Ganancias

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 feb 2026, 22:08 UTC

Charlas de Mercado

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 feb 2026, 21:51 UTC

Ganancias

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 feb 2026, 21:49 UTC

Ganancias

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 feb 2026, 21:39 UTC

Ganancias

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:36 UTC

Ganancias

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 feb 2026, 21:34 UTC

Ganancias

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:28 UTC

Adquisiciones, fusiones, absorciones

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 feb 2026, 21:23 UTC

Ganancias

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 feb 2026, 21:19 UTC

Ganancias

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 feb 2026, 21:17 UTC

Ganancias

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 feb 2026, 21:17 UTC

Ganancias

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:10 UTC

Ganancias

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:08 UTC

Ganancias

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 feb 2026, 21:07 UTC

Ganancias

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 feb 2026, 21:05 UTC

Ganancias

Palantir Technologies 4Q Net $608.7M >PLTR

2 feb 2026, 21:05 UTC

Ganancias

Palantir Technologies 4Q Rev $1.41B >PLTR

2 feb 2026, 21:05 UTC

Ganancias

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 feb 2026, 21:05 UTC

Ganancias

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 feb 2026, 21:05 UTC

Ganancias

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 feb 2026, 21:05 UTC

Ganancias

Palantir Technologies 4Q EPS 24c >PLTR

2 feb 2026, 20:40 UTC

Charlas de Mercado

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Comparación entre iguales

Cambio de precio

CorMedix Inc previsión

Precio Objetivo

By TipRanks

83.63% repunte

Estimación a 12 Meses

Media 14.25 USD 83.63%

Máximo 16 USD

Mínimo 13 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CorMedix Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para CorMedix Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

9.2 / N/ASoporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

295 / 352 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.